Wecksler AT - Search Results

1

Rationally designed multitarget agents against inflammation and pain.

Hwang SH, Wecksler AT, Wagner K, Hammock BD. Hwang SH, et al. Among authors: wecksler at. Curr Med Chem. 2013;20(13):1783-99. doi: 10.2174/0929867311320130013. Curr Med Chem. 2013. PMID: 23410172 Free PMC article. Review.

2

Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.

Hwang SH, Wagner KM, Morisseau C, Liu JY, Dong H, Wecksler AT, Hammock BD. Hwang SH, et al. Among authors: wecksler at. J Med Chem. 2011 Apr 28;54(8):3037-50. doi: 10.1021/jm2001376. Epub 2011 Apr 5. J Med Chem. 2011. PMID: 21434686 Free PMC article.

3

Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.

Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Inoue H, et al. Among authors: wecksler at. Cancer Biol Ther. 2011 Nov 1;12(9):827-36. doi: 10.4161/cbt.12.9.17680. Epub 2011 Nov 1. Cancer Biol Ther. 2011. PMID: 21878748 Free PMC article.

4

Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.

Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD. Hwang SH, et al. Among authors: wecksler at. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3732-7. doi: 10.1016/j.bmcl.2013.05.011. Epub 2013 May 15. Bioorg Med Chem Lett. 2013. PMID: 23726028 Free PMC article.

5

Biological evaluation of a novel sorafenib analogue, t-CUPM.

Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD. Wecksler AT, et al. Cancer Chemother Pharmacol. 2015 Jan;75(1):161-71. doi: 10.1007/s00280-014-2626-2. Epub 2014 Nov 21. Cancer Chemother Pharmacol. 2015. PMID: 25413440 Free PMC article.

6

Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.

Liao J, Hwang SH, Li H, Yang Y, Yang J, Wecksler AT, Liu JY, Hammock BD, Yang GY. Liao J, et al. Among authors: wecksler at. Cancer Lett. 2016 Feb 28;371(2):187-93. doi: 10.1016/j.canlet.2015.11.042. Epub 2015 Dec 9. Cancer Lett. 2016. PMID: 26683769 Free PMC article.

7

Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation.

Morisseau C, Wecksler AT, Deng C, Dong H, Yang J, Lee KS, Kodani SD, Hammock BD. Morisseau C, et al. Among authors: wecksler at. J Lipid Res. 2014 Jun;55(6):1131-8. doi: 10.1194/jlr.M049718. Epub 2014 Apr 27. J Lipid Res. 2014. PMID: 24771868 Free PMC article.

8

A novel p21 attenuator which is structurally related to sorafenib.

Wettersten HI, Hee Hwang S, Li C, Shiu EY, Wecksler AT, Hammock BD, Weiss RH. Wettersten HI, et al. Among authors: wecksler at. Cancer Biol Ther. 2013 Mar;14(3):278-85. doi: 10.4161/cbt.23374. Epub 2013 Jan 8. Cancer Biol Ther. 2013. PMID: 23298903 Free PMC article.

9

Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL 3rd, Gomes AV, Baar K, Weiss RH, Hammock BD. Wecksler AT, et al. Anticancer Drugs. 2014 Apr;25(4):433-46. doi: 10.1097/CAD.0000000000000079. Anticancer Drugs. 2014. PMID: 24525589 Free PMC article.

10

Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1.

Wecksler AT, Garcia NK, Holman TR. Wecksler AT, et al. Bioorg Med Chem. 2009 Sep 15;17(18):6534-9. doi: 10.1016/j.bmc.2009.08.005. Epub 2009 Aug 8. Bioorg Med Chem. 2009. PMID: 19716306 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page